Sarah Cannon Research Institute and US Oncology join forces to improve patient care
Two of the nation's leading oncology research firms combined staff and resources to expand access to cutting-edge treatment options
In 2022, McKesson Corporation and HCA Healthcare, Inc. announced an agreement to form a joint venture combining McKesson’s US Oncology Research (USOR) and HCA Healthcare’s Sarah Cannon Research Institute (“SCRI”). USOR is the research arm of McKesson’s The US Oncology Network and draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. SCRI, which is the research arm of Sarah Cannon, HCA Healthcare’s Cancer Institute, offers end-to-end clinical trial site support services with a deep expertise in early-phase oncology research and drug development as well as a specialized contract research organization (CRO).
The combination of two nationally leading oncology research institutes — US Oncology and Sarah Cannon Research Institute (SCRI) — resulted in significant benefits for patients of Swedish Medical Center: increased access to advanced care, drug development and clinical trials for patients and providers. US Oncology brings a staff specializing in oncology clinical trials to support SCRI’s expertise in early-phase oncology research and drug development.
The combined research network also brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the United States.
Sarah Cannon Research Institute provides advanced cancer care through personalized medicine at facilities across the globe including Swedish Medical Center. The network has earned a reputation for providing exceptional, compassionate cancer care while remaining committed to advancing the field of cancer care.
The new joint venture is led by Dee Anna Smith as CEO, along with Dr. Skip Burris as President, US Oncology Research’s Dr. Robert Coleman as Chief Medical Officer, and Dr. David Spigel as Chief Scientific Officer.
“In the last three decades, our collaborations have led to advancing treatment standards for the majority of new cancer therapies that are available to patients today. We believe that coming together with US Oncology Research will complement and strengthen our network so that we can continue to make a greater impact for people living with cancer,” said Smith.
Sarah Cannon Cancer Institute (SCCI) care offerings from diagnosis through survivorship will continue to operate as part of HCA Healthcare’s network of health systems as they do today. SCCI will continue to provide integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in the Swedish Medical Center community.
We are honored to work alongside our SCRI colleagues to advance science and transform cancer care. Learn more about the collaboration on Sarah Cannon’s website.